: Reported $15.5 million in free cash flow for Q3 fiscal 2026, a critical milestone for long-term sustainability.

: While adjusted EBITDA reached $18.5 million , Aurora still reported a net loss of $51.6 million in Q3 2026, driven by costs rather than top-line movement alone.

Aurora has demonstrated improving operational metrics despite bottom-line volatility.

: Global medical cannabis now accounts for 81% of total revenue and 95% of adjusted gross profit , with medical margins holding steady at 69% . Market Sentiment & Ratings